Press release
Illumina launches new software to enable tertiary analysis for oncology applications, and soon rare disease
As demand for clinical next-generation sequencing grows, Illumina Connected Insights enables user to streamline data interpretation and report generation to
About this update from Illumina, Inc.
[{"type":"text","content":"As demand for clinical next-generation sequencing grows, Illumina Connected Insights enables user to streamline data interpretation and report generation to inform precision care \nSAN DIEGO, March 27, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the release of Connected Insights, a new cloud-based software enabling tertiary analysis for clinical next-generation sequencing (NGS) data.\n\n \n \n \n \n \n \n\n \nExpanding on Illumina's Connected Software portfolio, Connected Insights is designed to streamline interpretation and reporting from a range of assay types, enabling labs to scale use of NGS and reduce turnaround time of clinical reporting via integration of third-party knowledge bases. The initial release will support somatic oncology applications, coinciding with the increasing use of comprehensive genomic profiling (CGP) for advanced tumors. Ultimately it is designed to support a diverse range of applications, soon including whole-genome sequencing (WGS) for rare disease. Connected Insights is commercially available in a limited number of countries. The product is undergoing beta testing in the US.\n\"We're seeing growing demand for NGS testing in health care systems, and with that comes the need for interpretation of large genomic data sets with complex health implications in a landscape of frequently changing guidelines and drug approvals,\" said Rami Mehio, head of global software and informatics at Illumina. \"Connected Insights complements our suite of NGS solutions to generate, analyze, annotate, and interpret data consistently—today and into the future.\"\nGrowing use of NGS leads to greater need for data solutions\nAlbrecht Stenzinger, whose lab was an early-access customer of Connected Insights, says there has been a growing push in recent years for more CGP for cancer therapy response prediction at the time of diagnosis, and for the use of whole-exome sequencing (WES) and WGS for rare and pediatric cancers. Along with that, advances in earlier cancer detection and target drug approvals for early-stage disease will fuel the need for further comprehensive testing.\n\"If you are generating this massive amount of data, you need to interpret this in a meaningful way,\" Stenzinger, director of the Center for Molecular Pathology at ...